HomeCompareIMXCF vs PFE

IMXCF vs PFE: Dividend Comparison 2026

IMXCF yields 216.17% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 IMXCF wins by $36.0K in total portfolio value
10 years
IMXCF
IMXCF
● Live price
216.17%
Share price
$0.93
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$85.6K
Annual income
$91.74
Full IMXCF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — IMXCF vs PFE

📍 IMXCF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIMXCFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IMXCF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
IMXCF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IMXCF
Annual income on $10K today (after 15% tax)
$18,374.41/yr
After 10yr DRIP, annual income (after tax)
$77.98/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, PFE beats the other by $22,241.92/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IMXCF + PFE for your $10,000?

IMXCF: 50%PFE: 50%
100% PFE50/50100% IMXCF
Portfolio after 10yr
$67.6K
Annual income
$13,175.23/yr
Blended yield
19.50%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

IMXCF
No analyst data
Altman Z
5.2
Piotroski
7/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IMXCF buys
0
PFE buys
0
No recent congressional trades found for IMXCF or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIMXCFPFE
Forward yield216.17%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%13.2%
Portfolio after 10y$85.6K$49.6K
Annual income after 10y$91.74$26,258.71
Total dividends collected$40.0K$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: IMXCF vs PFE ($10,000, DRIP)

YearIMXCF PortfolioIMXCF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$21,508$10,808.47$9,153$693.39+$12.4KIMXCF
2$33,877$10,863.26$8,593$849.25+$25.3KIMXCF
3$44,244$7,995.51$8,336$1,066.78+$35.9KIMXCF
4$52,221$4,879.55$8,437$1,384.80+$43.8KIMXCF
5$58,568$2,691.25$9,013$1,875.40+$49.6KIMXCF
6$64,078$1,410.43$10,306$2,680.72+$53.8KIMXCF
7$69,284$721.09$12,820$4,101.38+$56.5KIMXCF
8$74,499$364.34$17,673$6,826.70+$56.8KIMXCF
9$79,897$183.06$27,543$12,591.86+$52.4KIMXCF
10$85,581$91.74$49,560$26,258.71+$36.0KIMXCF

IMXCF vs PFE: Complete Analysis 2026

IMXCFStock

IMAX China Holding, Inc., an investment holding company, provides digital and film-based motion picture technologies in the People's Republic of China, Hong Kong, Macau, and Taiwan. It operates through three groups: IMAX Technology Network, IMAX Technology Sales and Maintenance, and New Business Initiatives and Other. The company engages in the digital re-mastering of Hollywood and Chinese language films into the IMAX format through a proprietary IMAX DMR conversion process and the exhibition of these films on the IMAX theatre network. It also designs, procures, and provides digital theatre systems at its exhibitor partners' movie theatres, as well as offers related project management, maintenance, and aftermarket services. In addition, the company provides technical research and development, consulting, service, training and marketing services for theatre systems and multimedia technology; and photographic equipment, virtual reality display equipment and related software and hardware, as well as engages in the provision of after-sales services, including installation. Further, it is involved in the wholesale, import, leasing, installing, maintenance, and repairing of movie theatre machinery, equipment, systems, photographic equipment, virtual reality display equipment, and related software; and research and development of software and hardware. Additionally, the company offers gift, handicraft, stationery commodity, clothing and apparel, and electronic products; and creative and conference, business consultation, and culture and art exchange and planning services, as well as operates ticket and publishing agency. It also engages in the design and production of advertising. The company was incorporated in 2010 and is headquartered in Shanghai, China. IMAX China Holding, Inc. is a subsidiary of Imax (Barbados) Holdings, Inc.

Full IMXCF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this IMXCF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IMXCF vs SCHDIMXCF vs JEPIIMXCF vs OIMXCF vs KOIMXCF vs MAINIMXCF vs JNJIMXCF vs MRKIMXCF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.